Say Hello to ReRx
At ReRx we provide ourselves in the best in class researchers from the worlds leading institutions bringing a combined 78 years of experience spanning the pharma, therapeutics, and research spaces to deliver our product to market.
Founders
Meet Our Team
Meet our talented team of professionals.
Dr. Näär is a professor of metabolic biology and vice chair at the Department of Nutritional Sciences and Toxicology at UC Berkeley.
Previously he was a tenured Professor of Cell Biology at Harvard Medical School and Massachusetts General Hospital Cancer Center for 17 years (2001-2018). His research focuses on understanding regulatory mechanisms driving pathological diseases and finding therapeutic solutions to address. His work has been used as a founding basis for multiple academic spinouts including a nasal spray developed for Covid-19 and antisense targeting of pathological RNAs associated with heart failure.
He received his Ph.D. in molecular pathology at UC San Diego/HHMI and conducted postdoctoral research at UC Berkeley/HHMI.
Previously he was a tenured Professor of Cell Biology at Harvard Medical School and Massachusetts General Hospital Cancer Center for 17 years (2001-2018). His research focuses on understanding regulatory mechanisms driving pathological diseases and finding therapeutic solutions to address. His work has been used as a founding basis for multiple academic spinouts including a nasal spray developed for Covid-19 and antisense targeting of pathological RNAs associated with heart failure.
He received his Ph.D. in molecular pathology at UC San Diego/HHMI and conducted postdoctoral research at UC Berkeley/HHMI.
Prabha Ibrahim
Chief Executive Officer
Dr. Ibrahim is a seasoned drug development expert with over 30 years of experience in the...
See MoreDr. Ibrahim is a seasoned drug development and discovery expert with over 30 years of experience in the biopharmaceutical/pharma industry.
She has played critical roles from identifying new candidates in early drug discovery, medicinal chemistry, and preclinical to clinical translation leading to development of multiple first-in-class medicines, including ZELBORAF® (vemurafenib), a BRAF inhibitor approved in 2011 for metastatic melanoma; TURALIO® (pexidartinib), a CSF-1R inhibitor approved in 2019 for symptomatic tenosynovial giant cell tumor; and LYFNUA (gefapixant), a P2X3 receptor antagonist approved in 2022 for refractory chronic cough (Japan & Switzerland). She has held multiple leadership positions such as CTO at Blade Therapeutics, Merck, and Afferent Therapeutics.
Dr. Ibrahim received her PhD in organic chemistry from the University of Victoria and conducted postdoctoral research at University of Colorado, Boulder.
She has played critical roles from identifying new candidates in early drug discovery, medicinal chemistry, and preclinical to clinical translation leading to development of multiple first-in-class medicines, including ZELBORAF® (vemurafenib), a BRAF inhibitor approved in 2011 for metastatic melanoma; TURALIO® (pexidartinib), a CSF-1R inhibitor approved in 2019 for symptomatic tenosynovial giant cell tumor; and LYFNUA (gefapixant), a P2X3 receptor antagonist approved in 2022 for refractory chronic cough (Japan & Switzerland). She has held multiple leadership positions such as CTO at Blade Therapeutics, Merck, and Afferent Therapeutics.
Dr. Ibrahim received her PhD in organic chemistry from the University of Victoria and conducted postdoctoral research at University of Colorado, Boulder.
Anders Naar
Chief Innovation Officer
Dr. Näär is a professor of metabolic biology and vice chair at the Department of Nutritional...
See More
Justin Lee
Chief Science Officer
Justin is completing his Ph.D. in metabolic biology and received his BA in molecular and...
See MoreJustin Lee
Chief Science Officer
Justin is completing his Ph.D. in metabolic biology and received his BA in molecular and cell biology, both at UC Berkeley.
His graduate research was done in the lab of Anders Näär, where he studied severe metabolic diseases such as obesity, diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD) and hepato-steatosis (MASH).
During his graduate studies, he was also awarded a Certificate of Entrepreneurship and Technology from the Sutardja Center for Entrepreneurship and Technology.
His graduate research was done in the lab of Anders Näär, where he studied severe metabolic diseases such as obesity, diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD) and hepato-steatosis (MASH).
During his graduate studies, he was also awarded a Certificate of Entrepreneurship and Technology from the Sutardja Center for Entrepreneurship and Technology.
With expert backgrounds from leading institutions
History
About Us
Spun out from UC Berkeley, ReRx is a pre-clinical biopharmaceutical company developing first-in-class therapies to address comorbidities related to servere metabolic diseases, such as obesity, diabetes, liver diseases, and more. Our highly experienced and dedicated team spans decades of experience in academia, industry, and drug development experience and is committed to bringing novel therapeutics to clinic.